Intellia Therapeutics, Inc. is 1.1x more valuable than Anbio Biotechnology by market capitalization ($1.70 B vs $1.50 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NNNN | NTLA |
|---|---|---|
| Market cap | $1.50 B | $1.70 B |
| US-listed rank | #2315 | #2213 |
| Revenue (latest FY) | $8.65M | $67.67M |
| Net income (latest FY) | $6.40M | -$412.69M |
| Net margin | 74.1% | -609.9% |
| P/E (trailing FY) | 234.2 | - |
| SEC filings | 40 | 687 |
Intellia Therapeutics, Inc. is 1.1x more valuable than Anbio Biotechnology by market capitalization ($1.70 B vs $1.50 B).
In their latest fiscal years, Anbio Biotechnology reported $8.65M in revenue while Intellia Therapeutics, Inc. reported $67.67M.
Full pages: Anbio Biotechnology and Intellia Therapeutics, Inc., or browse the full rankings.